Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Neurol.

Sec. Applied Neuroimaging

Research on Interpretable Machine Learning Models for Diagnosis and Staging of Mild Cognitive Impairment

Provisionally accepted
Chongyang  HeChongyang He1Yanyan  ZhouYanyan Zhou1,2Yi  ChenYi Chen1*Yang  JingYang Jing3
  • 1Department of Radiology, Chongqing Red Cross Hospital, Jiangbei District People’s Hospital, Chongqing, China., Chong Qing, China
  • 2Affiliated Hospital of Zunyi Medical University, Zunyi, China
  • 3Huiying Medical Technology Beijing Co Ltd, Beijing, China

The final, formatted version of the article will be published soon.

Background: Mild cognitive impairment (MCI) is a critical prodromal stage of Alzheimer's disease (AD), further categorized into early MCI (EMCI) and late MCI (LMCI). Early and accurate diagnosis is essential for effective prevention and intervention of AD. This study aims to develop an accessible and interpretable machine learning model to facilitate early diagnosis and subtype staging of MCI. Methods: A total of 268 participants were recruited from the ADNI, including cognitively normal individuals (CN, n=132), EMCI (n=95), and LMCI (n=41). Participants were randomly divided into training (80%) and testing (20%) cohorts. Multimodal data encompassing whole-brain T1-WI MRI radiomics, clinical neuropsychological scales and plasma protein biomarkers were collected. Logistic regression (LR) and random forest (RF) algorithms were employed to construct six unimodal models based on above three categories of features, as well as a combined model combining all features. Diagnostic performance for the three-class classification task (CN, EMCI, LMCI) was evaluated using receiver operating characteristic (ROC) curve. Furthermore, Shapley Additive Explanations (SHAP) were applied to quantify the contribution of individual features within the integrated model. Results: The combined model significantly outperformed unimodal models across all metrics, achieving macro_AUC=0.92, micro_AUC=0.91, and ACC=0.81 in the training set, and macro_AUC=0.87, micro_AUC=0.87, and ACC=0.76 in the testing set. The LR-based radiomics model ranked second. Models based solely on clinical neuropsychological scales or plasma protein biomarkers demonstrated comparatively lower classification performance. SHAP analysis highlighted neuropsychological scales (ADAS-Cog, MoCA) and radiomic features from critical brain regions (hippocampus, middle temporal gyrus, entorhinal cortex) as pivotal contributors to model efficacy. Conclusion: The integration of whole-brain structural MRI (sMRI) radiomics, neuropsychological scales, and plasma protein biomarkers significantly improves the precision of diagnosing and staging mild cognitive impairment (MCI). Radiomic characteristics derived from critical cerebral regions yield valuable pathological information that facilitates clinical interpretation. This methodology presents a promising strategy for the early identification and individualized management of MCI.

Keywords: Mild Cognitive Impairment, sMRI Radiomics, Neuropsychological scales, Plasmaprotein biomarkers, machine learning, Shapley additive explanations

Received: 18 Sep 2025; Accepted: 12 Nov 2025.

Copyright: © 2025 He, Zhou, Chen and Jing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yi Chen, cy94158@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.